These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27688833)

  • 1. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
    Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
    Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
    Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
    Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
    Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden associated with adverse events in patients with metastatic melanoma.
    Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
    J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
    Ghate SR; Li Z; Tang J; Nakasato AR
    Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
    Stenehjem D; Lubinga SJ; Wu A; Betts KA
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
    Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
    Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
    Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
    J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
    Garutti M; Bergnach M; Polesel J; Palmero L; Pizzichetta MA; Puglisi F
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
    Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
    Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
    Front Oncol; 2022; 12():865656. PubMed ID: 35530323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients.
    Appukkuttan S; Yao J; Partridge J; Kong SX; Parkin J; Freedland SJ
    J Med Econ; 2024; 27(1):145-152. PubMed ID: 38174553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.